Suscripción a Biblioteca: Guest
Critical Reviews™ in Therapeutic Drug Carrier Systems

Publicado 6 números por año

ISSN Imprimir: 0743-4863

ISSN En Línea: 2162-660X

The Impact Factor measures the average number of citations received in a particular year by papers published in the journal during the two preceding years. 2017 Journal Citation Reports (Clarivate Analytics, 2018) IF: 2.7 To calculate the five year Impact Factor, citations are counted in 2017 to the previous five years and divided by the source items published in the previous five years. 2017 Journal Citation Reports (Clarivate Analytics, 2018) 5-Year IF: 3.6 The Immediacy Index is the average number of times an article is cited in the year it is published. The journal Immediacy Index indicates how quickly articles in a journal are cited. Immediacy Index: 0.8 The Eigenfactor score, developed by Jevin West and Carl Bergstrom at the University of Washington, is a rating of the total importance of a scientific journal. Journals are rated according to the number of incoming citations, with citations from highly ranked journals weighted to make a larger contribution to the eigenfactor than those from poorly ranked journals. Eigenfactor: 0.00023 The Journal Citation Indicator (JCI) is a single measurement of the field-normalized citation impact of journals in the Web of Science Core Collection across disciplines. The key words here are that the metric is normalized and cross-disciplinary. JCI: 0.39 SJR: 0.42 SNIP: 0.89 CiteScore™:: 5.5 H-Index: 79

Indexed in

Novel 'Stereoscopic Response' Strategy Can Be Used in Combination Therapy

Volumen 35, Edición 4, 2018, pp. 369-390
DOI: 10.1615/CritRevTherDrugCarrierSyst.2018020591
Get accessGet access

SINOPSIS

Future cancer therapy will depend on combination therapy with multiple drugs to achieve maximum effects and minimum toxicity. Due to the complexity and significance of the tumor microenvironment (TME), it is vital to elucidate this complicated environment when designing a co-delivery system. There are numerous potent target sites in the TME to facilitate simultaneous and selective delivery. Currently, nanocarriers are used frequently in co-delivery systems for multiple antitumor treatments. Nanocarriers can efficiently deliver drugs and achieve synergistic effects, but the potent barriers in the TME and their inherent limitations have restricted their use. It is crucial to design an effected co-delivery system associated with the TME to achieve better anti-tumor activity, which we define as a "stereoscopic response." Although there are many obstacles in this field, the combination of simultaneous response in the TME with drug activity may present a promising strategy to achieve innovative, safe, and effective treatment.

CITADO POR
  1. Gu Zili, Da Silva Candido, Van der Maaden Koen, Ossendorp Ferry, Cruz Luis, Liposome-Based Drug Delivery Systems in Cancer Immunotherapy, Pharmaceutics, 12, 11, 2020. Crossref

  2. Fu Xianglei, Shi Yanbin, Zang Hengchang, Wang Qingjie, Wang Yongjun, Wu Hang, Qiu Shengnan, Shen Hua, Mo Fanyang, Zhang Yankun, Lin Guimei, Combination of oxaliplatin and POM-1 by nanoliposomes to reprogram the tumor immune microenvironment, Journal of Controlled Release, 347, 2022. Crossref

Portal Digitalde Biblioteca Digital eLibros Revistas Referencias y Libros de Ponencias Colecciones Precios y Políticas de Suscripcione Begell House Contáctenos Language English 中文 Русский Português German French Spain